BioSpace News Archive

The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA (www.cancerna.info), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.

Hummingbird Bioscience today announced that Jerome Boyd-Kirkup , Ph.D., Hummingbird Bioscience’s Chief Scientific Officer, will present at the 2nd Annual VISTA Symposium on September 23, 2022.

Corium, Inc. announced publication of its phase 1 healthy volunteer study results for ADLARITY (donepezil transdermal system) in the peer-reviewed Journal of Alzheimer’s Disease.

Theranica, a prescribed digital therapeutics company developing advanced digitally-connected neuromodulation devices for migraine and other pain conditions, announced today the publication of a new study comparing the effectiveness of Remote Electrical Neuromodulation (REN) to that of standard-care medications for the acute treatment of chronic migraine.

BioLineRx Ltd. today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 13,636,365 of the Company’s American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 13,636,365 ADSs, at a combined purchase price of $1.10 per ADS and associated warrant.

Aktis Oncology today announced the appointment of Shulamit Ron-Bigger, PhD, as Chief Operating Officer (COO).

Advanced NanoTherapies , Inc. today announced the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its SirPlux Duo Drug-Coated Balloon (DCB) for coronary artery disease in vessels less than 3.0mm.

Mirion Technologies, Inc. today announced that Dr. Sheila Rege, M.D. has been appointed to the Board of Directors, replacing Mr. Christopher Warren, who is stepping down.

Masimo announced the appointment of Blair Tripodi as Chief Operating Officer for the Masimo Consumer division, effective immediately.

Emulate, Inc. , a leading provider of next-generation in vitro models, today announced the launch of its new adeno-associated virus (AAV) transduction application for the Liver-Chip that enables gene therapy researchers to test the delivery efficiency and safety of AAV vectors in a validated, human-relevant model of the liver and get results in weeks, not months, as with animal models.